Fürst Per
Department of Oncology-Pathology, Karolinska Institutet, 171 64 Stockholm, Sweden.
Palliative Medicine, Stockholms Sjukhem Foundation, SE-112 19 Stockholm, Sweden.
Life (Basel). 2022 May 3;12(5):679. doi: 10.3390/life12050679.
The aim of this review is to summarize the current knowledge of low-dose methadone treatment in palliative cancer care. In Sweden, methadone is quite common in specialized palliative care, where almost a tenth of patients are prescribed this drug. Negative attitudes towards methadone do not seem to prevent it from being used for pain management, and by starting with low doses and then increasing slowly and gradually, methadone can apparently be introduced safely. It is still uncertain whether methadone has a better analgesic effect than other opioids. However, for pain relief in cancer patients with severe and complex cancer-related pain, NMDA receptor inhibition with methadone may, in selected cases, be an attractive alternative, especially in the form of low-dose supplements to other ongoing opioids. Due to long half-life and complex metabolism, the use of methadone requires an experienced physician and solid follow-up. Continuous administration of opioids, including low-dose methadone, has been proven effective and safe in reducing pain in dying patients without increasing the risk of confusion, regardless of age.
本综述的目的是总结目前在癌症姑息治疗中低剂量美沙酮治疗的相关知识。在瑞典,美沙酮在专科姑息治疗中相当常见,近十分之一的患者会使用这种药物。对美沙酮的负面态度似乎并未妨碍其用于疼痛管理,通过低剂量起始,然后缓慢逐渐增加剂量,美沙酮显然可以安全引入。美沙酮是否比其他阿片类药物具有更好的镇痛效果仍不确定。然而,对于患有严重且复杂的癌症相关疼痛的患者,在某些情况下,美沙酮抑制NMDA受体可能是一种有吸引力的选择,特别是作为其他正在使用的阿片类药物的低剂量补充形式。由于半衰期长且代谢复杂,美沙酮的使用需要经验丰富的医生和扎实的随访。连续使用阿片类药物,包括低剂量美沙酮,已被证明在减轻临终患者疼痛方面有效且安全,且不会增加意识模糊的风险,无论患者年龄如何。